Background: Chemotherapy is currently evaluated in order to enhance the efficacy of immune checkpoint blockade (ICB) therapy in colorectal cancer. However, the mechanisms by which these drugs could synergize with ICB remains unclear. The impact of chemotherapy on the PD-1/PD-L1 pathway and the resulting anticancer immune responses was assessed in two mouse models of colorectal cancer and validated in tumor samples from metastatic colorectal cancer patients that received neoadjuvant treatment. We demonstrated that 5-Fluorouracil plus Oxaliplatin (Folfox) drove complete tumor cure in mice when combined to anti-PD-1 treatment, while each monotherapy failed. This synergistic effect relies on the ability of Folfox to induce tumor infiltration by activated PD-1 C CD8 T cells in a T-bet dependent manner. This effect was concomitantly associated to the expression of PD-L1 on tumor cells driven by IFNg secreted by PD-1C CD8 T cells, indicating that Folfox triggers tumor adaptive immune resistance. Finally, we observed an induction of PD-L1 expression and high CD8 T cell infiltration in the tumor microenvironment of colorectal cancer patients treated by Folfox regimen. Our study delineates a molecular pathway involved in Folfox-induced adaptive immune resistance in colorectal cancer. The results strongly support the use of immune checkpoint blockade therapy in combination with chemotherapies like Folfox.
Introduction
Colorectal cancer (CRC) is one of the most common and aggressive cancer despite decades of research advances. Although not given with a curative intent, combined chemotherapies such as 5-Fluorouracil plus Oxaliplatin (Folfox) are routinely used as first-line treatment for advanced CRC. 1, 2 However, the appearance of acquired pharmacological resistances to these therapies in most patients limits their antitumor effect, leading to tumor escape.
Evidence supports the importance of the immune cell infiltrate in the prognosis of CRC. During the past two years several studies conducted in many cancers brought to light the tremendous clinical efficacy of immunotherapies targeting immune checkpoints such as the inhibitory molecule PD-1 (programmed cell death-1) or its ligand PD-L1. 3, 4 However in CRC the majority of patients, especially microsatellite stable (MSS) tumors, do not respond to these treatments. 3, 5, 6 Recent literature highlights a range of factors such as the intratumoral immune contexture that is involved in the heterogeneous responses and failures of immune checkpoint blockade (ICB). 7, 8 Indeed, patients with high pre-existing CD8 T cell infiltrate in the tumor microenvironment (TME) are more responsive to such immunotherapies. 3, 9, 10 Thus, in a clinical context, a desirable outcome would be to reinstate a suitable immunological environment to sensitize colorectal tumors to immune checkpoint inhibitors. For this, an approach is to combine them with other treatments that stimulate T cell immunity like chemotherapeutic agents. 11, 12 Studies in preclinical models indeed suggest that some chemotherapies can improve the anticancer efficacy of ICB. 13 Some cytotoxic drugs have immunogenic properties that can promote the activation of the immune system. 12, 14, 15 Indeed, 5-Fluorouracil (5-FU) was shown to selectively deplete Myeloidderived Suppressor Cells (MDSCs) in vivo, 16 while Oxaliplatin can trigger an immunogenic form of tumor cell death (ICD) through cell surface exposure of calreticulin (CRT), HMGB1 and ATP release. 15, 17 These processes can contribute to the induction of CD8 T cell antitumor immunity and therefore act to re-establish the cancer-immunity cycle described by Chen and Mellman. 18 It also justifies the current clinical evaluation of Folfox in combination with immune checkpoint inhibitors in colorectal cancer. However, the molecular mechanisms by which chemotherapy could sensitize tumors to immunotherapy are still elusive.
Here, we report in mouse colorectal cancer models that Folfox induces complete tumor cure when combined with anti-PD1 therapy. We demonstrate that Folfox promotes in the TME the expression of both PD-1 on activated CD8 T cells and PD-L1 on tumor cells, thereby driving tumor adaptive immune resistance. Our findings thus indicate that the blockade of the PD-1/PD-L1 pathway prevents the adaptive immune resistance induced by Folfox in colorectal cancers.
Results

Folfox combined with anti-PD-1 therapy induces complete colorectal tumor cure
We tested the ability of chemotherapeutics commonly used to treat human colorectal cancer to potentiate anti-PD-1 therapy. To this end, CT26 colorectal tumor-bearing Balb/c mice were treated with cytotoxic drugs in combination or not with anti-PD1 therapy. These drugs were administrated as monotherapy (5-Fluorouracil, 5-FU; Mitomycin C, MMC; or Oxaliplatin, OX) or in combination 5-FU plus MMC (5-FU/MMC) or 5-FU plus OX (Folfox). Contrary to OX and MMC monotherapies, 5-FU, 5-FU/MMC and Folfox regimens promoted a slight delay of tumor growth before tumor relapse (Fig. 1A) . Importantly, in combination with anti-PD-1 therapy, Folfox was the only treatment that led to complete and long-lasting cancer cure (Fig. 1A,  B) . Data of pooled experiments are represented in Fig. 1C .
Similar results were also observed in C57BL/6 mice bearing MC38 colon tumors ( Supplementary Fig. 1A and B) . In addition, we did not observe any cancer recurrence in Folfox/anti-PD-1 cured mice and those animals were still protected against a CT26 tumor rechallenge but not against the control 4T1 mammary adenocarcinoma tumor ( Supplementary Fig. 1C ). These data strongly suggest that Folfox administration creates a suitable TME that renders colorectal tumors sensitive to PD-1 blockade in vivo.
Folfox induces functional PD-1 C CD8 TILs in the tumor microenvironment Next, we evaluated the effect of Folfox on immune cells within the tumor bed. Because 5-FU selectively eliminates immunosuppressive Myeloid-derived suppressor cells (MDSCs) in vivo, 16 we first investigated whether Folfox induced MDSC depletion. We found that, like 5-FU, Folfox induced MDSC depletion in vivo and had no effect on regulatory T cells (Tregs) (Supplementary Fig. 2 ). Thus the ability of Folfox to deplete MDSCs is not sufficient to explain the robust tumor regression when combined with anti-PD1 therapy (Fig. 1) .
By analyzing tumor-infiltrating lymphocytes (TILs), we found that chemotherapies led to variable levels of CD8 T cell infiltrate in tumors. Except for MMC, Folfox and other chemotherapies led to an increase of CD8 TILs compared to untreated control ( Fig. 2A) . But unlike other treatments, Folfox induced strong levels of IFNɣ-producing CD8 TILs both ex vivo and in response to AH-1/H2-L d peptide expressed by CT26 tumor cells (Fig. 2B,C and Supplementary Fig. 3 ).
Using RNA-sequencing, we found that CD8 TILs from Folfox-treated mice have increased expression by more than 3-fold of genes encoding inhibitory receptors such as PD-1 (Pdcd1), Tim-3 (Havcr2), CTLA-4 (Ctla4), LAG3 (Lag3), TIGIT (Tigit) and NKG2A (Klrc1) (Fig. 3A) . The cell surface analysis of PD-1 and Tim-3, the two main inhibitory receptors commonly used to characterize exhausted T cells, 19, 20 was performed in tumorbearing mice treated by chemotherapy. As shown in Fig. 3B , we observed that chemotherapies induced variable levels of PD-1 and Tim-3 expression on CD8 TILs compared to control. Interestingly, CD8 TILs co-expressing PD-1 and Tim-3 thought to be dysfunctional cells were particularly present in the groups of mice treated with Folfox (»34%) or 5-FU (»24%) as compared to OX (»12%) (Fig. 3C ). Of note, the expression of PD-1 and Tim-3 on CD8 T cells was restricted to the tumor site as no induction of these two receptors was found in the spleen or tumor-draining lymph nodes of the treated mice (data not shown). Similar results were found in C57BL/6 mice bearing MC38 colon tumors ( Supplementary Fig. 4 ).
Because Folfox promotes high levels of PD-1 C Tim-3 C CD8 TILs, we asked for the functionality of these cells. To this end, we sorted CD8 TILs from Folfox-treated CT26 tumor-bearing mice according to PD-1 and Tim-3 expression and studied their respective functions. Quantitative RT-PCR indicated that PD-1
C
Tim-3
¡ and PD-1 C Tim-3 C cells featured high expression of genes encoding immune effector factors such as IFNg (Ifng), Granzyme B (GrzmB) or Perforin (Prf1) compared to PD-1 ¡ and Tim-3 ¡ negative cells (Fig. 3D ). In addition, more than 85% of CD8 TILs from Folfox or control mice were CD44 hi CD62L low , which is consistent with an effector memory phenotype (data not shown). 21 Additionally, a kinetic analysis revealed that the frequency of PD-1 C CD8 TILs from Folfox-treated mice gradually decreased overtime along with their effector functions, suggesting that inhibitory signals drove their dysfunction ( Fig. 3E and Supplementary Fig. 5A,B) . Consequently, adding anti-PD1 blocking antibody to Folfox in vivo prevents this CD8 T cell dysfunction and ensured a sustained antitumor response (Fig. 3F) . By contrast, anti-PD-1 therapy was not able to unleash or increase the antitumor activity of CD8 TILs from 5-FU-treated mice (Fig. 3F) . These results indicate that Folfox favors the early infiltration of tumors by functional PD-1 C CD8 T cells, a parameter which seems to be required to its synergistic effect with anti-PD1 therapy in vivo.
T-bet drives PD-1
C expression on functional tumorinfiltrating CD8 T cells elicited by Folfox
We next searched for the molecular mechanism that controls the Folfox-induced PD-1 C CD8 TILs effector function. We focused our investigation towards two transcription factors, T-bet and Eomes, involved in CD8 T cell effector and memory differentiation. [22] [23] [24] Compared to untreated or 5-FU-treated mice, higher level of T-bet (Tbx21) mRNA was detected in CD8 TILs from Folfox treated-mice ( Fig. 4A and Supplementary Fig. 6A ). This induction of T-bet by Folfox was especially found in PD-1 C CD8 T cells ( Supplementary Fig. 6B ). In contrast, the expression of Eomes (Eomes) on CD8 T cells remained globally unaltered ( Fig. 4A and Supplementary  Fig. 6A ).
To explore the role of T-bet, we used T-bet fl/fl CD4-Cre mice (Tbx21 floxed mice crossed to CD4 Cre mice) and Eomes fl/fl CD4-Cre mice (Eomes floxed mice crossed to CD4 Cre mice), which respectively conditionally lack T-bet and Eomes expression in CD4 and CD8 T cells. Following treatment with Folfox, we found that the absence of Tbx21 led to a stronger decrease in PD-1 and Tim-3 expression as compared to Eomes-deficient mice (Fig. 4B) . Accordingly, the frequency of PD-1 C and Tim-3 C CD8 T cells drastically dropped in mice lacking T-bet, while no obvious changes were detected in the absence of Eomes ( Fig. 4C and D) . Furthermore, we observed that the lack of Tbx21 but not Eomes in T cells also completely abrogated effector function of CD8 TILs (Fig. 4E) . Accordingly, the antitumor effect of Folfox was impaired in absence of Tbx21 (Fig. 4F ). This demonstrates that, following Folfox treatment, not only Tbet controls the induction of PD-1 C CD8 T cells in the TME but it also dictates the ability of Folfox to induce anticancer immunity.
PD-L1 expression on tumor cells induced by Folfox in vivo is driven by IFNg-producing CD8 T cells
Next, we assessed whether Folfox can also modulate PD-L1 on tumor cells. We found that Folfox administration led to a marked increase of the expression of the Cd274 gene encoding PD-L1, and of PD-L1 protein expression (78 § 8% in Folfox vs 31 §7% in untreated control) on tumor cells both in CT26 and MC38 tumor models ( Fig. 5A-D) . Kinetic analysis revealed that PD-L1 expression on tumor cells peaked 8 days after treatment initiation (Fig. 5E ). We examined whether other drugs can modulate PD-L1 induction. As shown in Fig. 5F , OX also promoted PD-L1 expression on tumor cells in vivo but to at lesser extent than Folfox while 5-FU and MMC did not.
Because we did not find any correlation between PD-L1 induced by drugs on tumor cells in vitro and in vivo (Supplementary Fig. 7 ), we assumed that PD-L1 expression could be driven through an indirect mechanism. To test this, we first assessed the levels of PD-L1 expression on tumor isolated from immunocompetent or T-cell deficient Nude mice treated or not with Folfox. We observed that PD-L1 on tumor cells was drastically reduced in immunodeficient mice, indicating that T cells play a key role in PD-L1 expression upon Folfox treatment (Fig. 6A) . Interestingly, depletion of CD8, but not CD4 T cells, suppressed Folfox-induced PD-L1 expression on tumor cells, demonstrating that CD8 T cells are responsible for PD-L1 expression following Folfox (Fig. 6B ). As expected, neutralization of IFNg in vivo significantly decreased PD-L1 expression on tumor cells (Fig. 6C) .
Next, we searched for a potential mechanism involved in IFNg-dependent PD-L1 expression on tumor cells. ERK, mTOR and STAT signaling have been previously reported to modulate PD-L1 expression in cancer cells. 25 Upon treatment of CT26 cells in vitro with IFNg, we found enhanced phosphorylation of STAT1 but not of ERK and mTOR (Fig. 6D) . Furthermore, we found an upregulation of IRF1 expression which was reported to be regulated by STAT1 and was proposed to drive PD-L1 expression 26 ( Fig. 6D) . Accordingly, IFNg treatment induced the binding of IRF1 to the promoter of PD-L1 gene (Cd274) (Fig. 6E) . Silencing IRF1 using siRNA confirmed that IRF1 was required for PD-L1 expression in response to IFNg in CT26 cancer cells (Fig. 6F) .
Taken together, these results clearly indicate that in our model IFNg-secreting CD8 TILs are the main contributor to PD-L1 induction on tumor cells following Folfox administration.
Immunogenic tumor cell death induced by Folfox promotes high levels of PD-L1 on tumor cells
Because ICD induced by chemotherapies can stimulate CD8 T cells, 12, 14 we hypothesized that Folfox-driven PD-L1 expression may be related to ICD. We first evaluated the ability of Folfox and other chemotherapies to induce ICD in vitro in the CT26 model. By monitoring cell surface calreticulin (CRT) expression and HMGB1 release, we observed that Folfox highly induced these two ICD hallmarks as compared to other drugs ( Fig. 7A  and B) . Interestingly, a strong positive correlation was found between CRT exposure on CT26 tumor cells in vitro and PD-L1 induction on tumor cells in vivo by chemotherapies (p < 0.0001) (Fig. 7C) . Comparable results were obtained with MC38 colorectal cancer as well as with LLC1 mouse lung cancer models treated with Doxorubicin (Doxo), an ICD inducer, 15 suggesting that this effect could be extended to other tumor types ( Supplementary Fig. 8 ).
To confirm that ICD accounts for PD-L1 induction in vivo, we monitored PD-L1 expression on tumor cells in Toll-like receptor 4 (TLR4) deficient mice that cannot mount an immune response following ICD induction. TLR4 is indeed one of the receptors of HMGB1 and reported to be required to tumor control upon ICD induction. 13, 27 In the absence of TLR4, the induction of PD-L1 expression on tumor cells by Folfox is abrogated (Fig. 7D) , indicating that ICD is required for PD-L1 expression on tumor cells in vivo. Folfox neoadjuvant chemotherapy stimulates ICD along with increased CD8 infiltrate and PD-L1 expression in the tumors of metastatic colorectal cancer patients
We eventually addressed the effect of Folfox chemotherapy on the TME in humans. To this end, we analyzed 9 tumor tissue samples from patients with stage IV colorectal cancer before and after 6 cycles of neoadjuvant Folfox regimen before surgery. The patients' main disease characteristics are depicted in Table 1 . Our results revealed that PD-L1 expression was significantly higher in tissue samples after Folfox and this upregulation was noted in 5 out of 9 (56%) of patients (Fig. 8) . Interestingly, Folfox chemotherapy was associated with an increase of CD8 TILs as well as with higher expression of LC3B puncta, a marker of autophagy and also reported as a surrogate marker of ICD induction in humans (Fig. 8) . Taken together, these results support the links between Folfox-induced ICD, CD8 T cell infiltration and PD-L1 expression in human colorectal cancers.
Discussion
In this study, we investigated the rationale to combine chemotherapy with anti-PD1 therapy in colorectal cancer. By using two mouse colorectal cancer models, we found that Folfox plus anti-PD-1 treatment induced complete and long-lasting tumor cures in mice.
We found that Folfox induced strong expression of immune checkpoints such as PD-1 on activated CD8 TILs. In return, the IFNg secreted by Folfox-induced CD8 T cells drove PD-L1 expression on tumor cells. Similar effect of Folfox was observed in colorectal cancer patients. Indeed, an increased CD8 cell infiltrate and tumor PD-L1 expression were found in metastatic colorectal cancer patients after Folfox neoadjuvant therapy. These observations are in line with the concept of adaptive immune resistance that has been defined as a dominant mechanism of tumor escape in the tumor microenvironment. 28 Thus, the upregulation of PD-L1 by tumor cells in response to IFNg secreted by CD8 T cells is an adaptive immune resistance mechanism to Folfox. This finding could also represent an escape mechanism to Folfox therapy in colorectal cancer.
In mouse and human melanoma, the success of immune checkpoint blockade relies on the inhibition of adaptive immune resistance. 10, 28 In our study, we demonstrated that the efficacy of Folfox/anti-PD-1 combination in mice is strongly linked to the disruption of adaptive immune resistance and not to a mere additive effect of these therapies. Indeed, anti-PD-1 alone was not able to control tumor growth as already reported in colorectal cancer patients. 5, 6 The efficacy of anti-PD-1 immunotherapy is associated to the pre-existence of abundant PD1 hi CD8 T cells in TME. 7, 10, 29 We showed that Folfox promoted activated tumor-specific PD-1 C CD8 T cells in the TME, creating a suitable environment for the action of anti-PD-1 therapy. Besides, this could also explain the lack of efficacy of anti-PD-1 when combined to other drugs such as 5-FU or MMC, which do not stimulate functional PD-1 C CD8 TIL in vivo. Of note, we observed in our mouse model that the Folfox-induced PD-1 C CD8 TILs decrease together with their antitumor function after two weeks, suggesting that the administration of immune checkpoint inhibitors should be given concomitantly or early after Folfox therapy.
We further deciphered the mechanism by which Folfox induced adaptive immune resistance. PD-1 induction on CD8 TILs was dependent on T-bet, while PD-L1 on tumor cells required IFNg/ IRF1 signaling. This T-bet-dependent PD-1 expression is in discrepancy with studies conducted in mouse models of chronic viral infection reporting that T-bet repressed PD-1 expression on CD8 T cells. 30, 31 It has however been described that T-bet was expressed by early activated CD8 T cells. 23 In our study, T-bet expression was assessed early after treatment, possibly explaining why we found a co-expression of T-bet and PD-1 in Folfox-induced CD8 TILs.
It has been reported that combining MDSC-targeted therapy with immune checkpoint blockade induced a robust synergistic 
e1433981-8
antitumor effect through an increased infiltration. 32 Among the tested cytotoxic drugs, 5-FU was shown to deplete MDSC and we observed that Folfox has similar effect. In contrast to Folfox, the combination of 5-FU to anti-PD-1 does not lead to tumor cure, suggesting that the depletion of MDSC is not sufficient in this context to allow full CD8 T cell activation.
Chemotherapies inducing immunogenic tumor cell death (ICD) were reported to synergize with immunotherapy in a CD8 T cell-dependent manner. 13 We further here demonstrate that ICD was involved in the tumor adaptive immune resistance triggered by Folfox in vivo. Indeed, Folfox generated high expression of calreticulin and HMGB1. In addition, PD-L1 induction by Folfox was decreased in TLR4-deficient mice that cannot mount a suitable immune response following ICD. 27 Furthermore, in colorectal cancer patients treated by Folfox, LC3B (a surrogate marker of ICD 33, 34 ) is induced along with high CD8 infiltration and PD-L1 expression in tumor. Thus combining LC3B, CD8 and PD-L1 in TME could represent a predictive biomarker to anti-PD-1 therapy efficacy in colorectal cancer patients. 3, 8 In conclusion, we described for the first time PD-1/PD-L1 pathway as part of an adaptive immune resistance cycle induced by Folfox chemotherapy. The blockade of the PD-1/ PD-L1 pathway prevents the emergence of such resistance mechanism to the treatment in vivo. Our study thus provides a robust rationale to use therapies like Folfox in combination with immune checkpoint inhibitors in cancer patients.
Materials and methods
Experimental models and subject details
For in vivo animal studies, animals were used between 6 and 8 weeks of age. Female BALB/cAnNRj and C57BL/6NRj mice were purchased from Centre d' elevage Janvier (Le Genest St Isle, France). TLR4-KO mice were kindly provided by Dr. Ryffel. Floxed Tbx21 and Eomes mice as well as CD4-Cre were purchased from JAX. All animal experiments were performed under protocols approved by the local ethical committee and were carried out according to the good laboratory practices defined by the animal experimentation Rules in France. For human studies, tumor samples were collected at the Centre Georges François Leclerc (Dijon, France) and all patients had given their written consent. Tumor tissue samples from biopsies were collected from 9 stage IV metastatic colorectal cancer patients at the baseline and after 6 cycles of Folfox neoadjuvant chemotherapy before surgery. For mouse tumor cell lines, CT26 (which exhibits a microsatellite stable profile 35 ) and MC38 colon carcinoma cells, and LLC1 lung carcinoma cells were cultured in complete medium: RPMI 1640 with glutamax-1 (Lonza) supplemented with 10% Fetal Calf Serum (Lonza), 1% Penicillin, Streptomycin, Amphotericin B (Gibco). All cells were routinely tested for mycoplasma contamination using Mycoalert Mycoplasma Detection Kit (Lonza) and found negative. e1433981-10this criterion were excluded. All chemotherapies were obtained from the Centre George François Leclerc, except for mitomycin C (MMC) (Sigma). 5-FU, OX, MMC and Irinotecan were administered i.p. once at 50 mg/kg, 6 mg/kg, 2 mg/kg and 20 mg/kg respectively. Doxorubicin (Doxo) was given once i.t. at 120 mg per mouse. Gemcitabine (Gem) was given once i.p. at 75 mg/kg. Mice from control groups were injected with the solvent used to dissolve the drugs. Anti-mouse PD-1 antibody (RMP1-14; BioXcell) injections were initiated concomitantly with the chemotherapy treatment, then given i.p. at 200 mg per mice twice a week until the tumor reached >250 mm 2 or, when appropriate, until complete tumor regression. Mice whose tumors exceeded 250 mm 2 ; were euthanized due to ethical reasons and survival curves were plotted. For rechallenge experiments, tumor-free mice were injected with 2.10 6 CT26 on the left flank and 2.10 5 4T1 on the right flank. For CD8, CD4 and IFNg depletion, anti-mouse CD8 (YTS 169.4; BioXcell), CD4 (GK1.5; BioXcell) or IFNg antibodies (XMG1.2; BioXcell) were used. Anti-CD8 antibody was administrated i.p. once at 500 mg per mice, anti-CD4 twice every two days at 300 mg per mice and anti-IFNg twice a week at 300 mg per mice.
ELISpot IFNg assay
Freshly percoll-purified tumor-infiltrating lymphocytes were incubated at 5.10 4 cells per well in duplicate in Elispot IFNg plates (Diaclone) and in the presence of medium or AH-1/H2-Ld peptide (10 mg/mL, Proimmune) derived from gp70 antigen expressed by CT26 tumor cells. Plates were incubated for 18 H at 37 C and spots were revealed following the manufacturer's instructions (GenProbe). Spot-forming cells were counted using the "C.T.L. Immunospot" system (Cellular Technology Ltd.).
Flow cytometry
Fluorochrome-conjugated anti-PD-L1 (10 F.9 G2), anti-CD45 (30-F11), anti-CD11b (M1/70), anti-CD8 (53-6.7), anti-CD4 (GK1.5), anti-CD3 (145-2C11), anti-Tim3 (RMT3-23) and antiTNFa (MP6-XT22) were from Biolegend. Anti-PD1 (J43) was from eBioscience. CD107 a (1D4B) and anti-IFNg (XMG1.2) was from BD Bioscience. For selection of tumor cells, after Percoll performed to isolate tumor-infiltrating lymphocytes, cells from the upper phase were collected. First, tumor cells were gated based on FSC/SSC parameters using in vitro tumor cell line as reference. Then CD45-7AAD-viable tumor cells were selected. All events were acquired by a BD LSR-II cytometer equipped with BD FACSDiva software (BD Biosciences) and data were analyzed using FlowJo software (Tree Star, Ashland, Oregon).
Western blotting
Cells were plated at a density of 1 £ 10 5 cells onto 24-well plate. After 24 h cells were grown in X-Vivo 15 medium (Lonza) during 4 h and treated with mouse IFNg (Miltenyi, #130-105-790) at working concentration of 10 ng/ml, diluted in X-Vivo 15 medium. 24 hours after the treatment, whole cell extracts were prepared in boiling buffer (1% SDS, 1 mM sodium orthovanadate and 10 mMTris, pH 7.4) in the presence of complete protease inhibitors (Roche Diagnostics). The viscosity of samples was diminished by sonication. Protein concentrations were measured with a Bio-Rad DC protein assay kit. Protein lysates were incubated in loading buffer (125 mMTris-HCl, pH 6.8, 10% b-mercaptoethanol, 4.6% SDS, 20% glycerol and 0.003% bromophenol blue) and heated at 95 C for 5 min, then were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE, 12%) and were transferred by electroblot to nitrocellulose membrane before analysis with a chemiluminescence detection kit (ThermoFisher). The primary antibodies used for immunoblotting directed against IRF1 were from Santa Cruz Biotechnologies. p-STAT1, STAT1, p-ERK, ERK, p-mTOR, mTOR were from Cell Signaling. b-actin was from Sigma-Aldrich.
ChIP assay
ChIP assays were performed with a ChIP-IT express kit (Active Motif Europe) according to the manufacturer's instructions. After enzymatic digestion, DNA was immunoprecipitated overnight at 4 C with 3 mg of anti-mouse IRF1 (H-205, Santa Cruz, #sc-13041) or 2 mg of negative control immunoglobulin. After the addition of protein G beads, the mixture of protein G, antibody and chromatin was washed and eluted from the protein G with supplied buffers. Then, cross-linking was reversed and samples were analyzed by quantitative PCR. Oligonucleotide sequences are: promoter PDL1: forward 5 0 -GGTTCCACTCCCACCCAAA-3 0 ; reverse 5 0 -AACCGGGCTGCTACTGAGAG-3 0 .
SiRNA transfection
Cells were plated at a density of 1 £ 10 5 cells onto 24-well plate. After 24 H, the cells were transfected with IRF-1 siRNA (siRNA ID s7501) or control siRNA using Lipofectamine 2000 (Invitrogen) according to the manufacturer's recommendations. One day after the transfection, cells were grown in X-Vivo 15 medium (Lonza) during 4 h and treated with mouse IFNg (Miltenyi) at working concentration of 10 ng/ml, diluted in XVivo 15 medium. 24 hours after the treatment, total RNA was isolated using Trizol reagent (Invitrogen), according to the manufacturer's protocol. cDNA were generated using M-MLV Reverse Transcriptase (Invitrogen), which was amplified by real-time quantitative PCR (RT-qPCR) with the SYBR Green method using the 7500 Fast Real Time PCR system (Applied Biosystems). Expression was normalized to the expression of mouse Actb. Primers designed to assess the expression of IRF1 are, forward 5 0 -AGGCATCCTTGTTGATGTCC-3 0 and reverse 5 0 -AATTCCAACCAAATCCCAGG-3 0 ; and of PD-L1 are, forward 5 0 -CTCGCCTGCAGATAGTTCCC-3 0 and reverse 5 0 -GTCCAGCTCCCGTTCTACAG-3 0 .
Transcriptome analyses
Tumor-infiltrating CD8 T cells from CT26-tumor bearing mice treated with Glucose 5% (control) or Folfox when tumors reached 50-70 mm 2 were sorted by flow cytometry 8 days following treatment. CD8 TILs cells coming from 2 independent experiments with 8-10 pooled tumors for each experiment were used. Splenic CD8 T cells from 2 na€ ıve mice were used as reference. Total mRNA was isolated using Trizol (Gibco Life Technologies) according to the manufacturer's instructions. rRNA from total RNA extracted were removed with NEBNextrRNA depletion kit (New England BioLabs). 100 ng of RNA depleted of rRNA was used for the library preparation with a NEBNext Ultra RNA library kit for Illumina according to the manufacturer's instructions (New England BioLabs). RNA sequencing was performed on a NextSeq 500 device (Illumina). The libraries were sequenced with paired-end 75-base pair 'reads'. FASTQ files were mapped with the BWA software package (mm10 National Center for Biotechnology Information assembly of the Mus musculus genome) for Illumina. Analysis was performed with the splice junction mapper TopHat for Illumina. The files generated were processed with Cufflinks software to obtain annotated expressed genes in each studied subtype. Heatmaps of selected genes were generated using R software (http://www.R-project.org).
Detection of immunogenic tumor cell death induction
For fluorescence detection of cell surface CRT, tumor cells were applied on a microscope slide plated onto 12-well plate. Cells were grown 24 H in complete medium (RPMI 10% Fetal Bovine Serum 1% Penicillin-Amphotericin B), then treated for 6 H with or without 5-FU (10 mM), Oxaliplatin (OX, 50 mM), Mitomycin C (MMC, 20 mM) or 5-FU/OX (Folfox, 10 mM/ 50 mM). Cells were fixed at room temperature with 0.25% paraformaldehyde (PFA) for 5 min then incubated for 30 min at 4 C in PBS 3% BSA, then incubated 30 min at 4 C with primary rabbit anti-mouse anti-CRT (1:200, Abcam, ab2907) in PBS 3% BSA. The secondary antibody Alexa488-labeled donkey anti-rabbit IgG H&L (1:500, Abcam, ab150073) added in PBS 3% BSA for 30 min at 4 C. Cells were then fixed in PFA 4% for 20 min at 4 C. To measure HMGB1 release, cells were incubated for 24 H in presence of the different chemotherapies as described above. HMGB1 levels were measured by ELISA (Chondrex) according the manufacturer's instructions.
